The DOI matches its Crossref record.
Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double‐blind, placebo‐controlled study
Abstract
Objective: To evaluate the efficacy and safety of apremilast, a novel, orally available small molecule that specifically targets phosphodiesterase 4, in the treatment of active psoriatic arthritis (PsA). Methods: This phase II, multicenter, randomized, double‐blind, placebo‐controlled study included the following: a 12‐week treatment phase, with patients receiving placebo, apremilast 20 mg twice per day, or apremilast 40 mg once per day; a 12‐week treatment‐extension phase, with patients in the placebo group re‐randomized to receive apremilast; and a 4‐week observational phase after treatment cessation. The primary end point was the proportion of patients achieving the American College of Rheumatology criteria for 20% improvement (ACR20) at week 12. Safety assessments included adverse events (AEs), physical examinations, vital signs, laboratory parameters, and electrocardiograms. Results: Of the 204 patients with PsA who were randomized to a treatment group, 165 completed the treatment phase. At the end of the treatment phase (week 12), 43.5% of patients receiving apremilast 20 mg twice per day ( P < 0.001) and 35.8% of those receiving 40 mg once per day ( P = 0.002) achieved an ACR20 response, compared with 11.8% of those receiving placebo. At the end of the treatment‐extension phase (week 24), >40% of patients in each group (patients receiving apremilast 20 mg twice per day, patients receiving apremilast 40 mg once per day, and patients in the placebo group re‐randomized to receive apremilast) achieved the ACR20 level of improvement. Most patients in the treatment phase (84.3%) and treatment‐extension phase (68.3%) reported ≥1 AE. Diarrhea, headache, nausea, fatigue, and nasopharyngitis were reported most frequently; most events were mild or moderate. No clinically relevant laboratory or electrocardiographic abnormalities were reported. Conclusion: Treatment with apremilast at a dosage of 20 mg twice per day or 40 mg once per day demonstrated efficacy in comparison with placebo and was generally well tolerated in patients with active PsA. The balance of efficacy, tolerability, and safety supports further study of apremilast in PsA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Gossec, L., Smolen, J. S., Ramiro, S., de Wit, M., Cutolo, M., Dougados, M., Emery, P., Landewé, R., Oliver, S., Aletaha, D., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208337 · Cited by 920
Self-citationSingh, J. A., Guyatt, G., Ogdie, A., Gladman, D. D., Deal, C., Deodhar, A., Dubreuil, M., Dunham, J., Husni, M. E., Kenny, S., et al. (2019) · Arthritis & Rheumatology · doi:10.1002/art.40726 · Cited by 493
Singh, J. A., Guyatt, G., Ogdie, A., Gladman, D. D., Deal, C., Deodhar, A., Dubreuil, M., Dunham, J., Husni, M. E., Kenny, S., et al. (2019) · Arthritis Care & Research · doi:10.1002/acr.23789 · Cited by 466
The Inflammatory Response in Psoriasis: a Comprehensive Review
Deng, Y., Chang, C., & Lu, Q. (2016) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-016-8535-x · Cited by 416
Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity
Schafer, P. H., Parton, A., Capone, L., Cedzik, D., Brady, H., Evans, J. F., Man, H.-W., Muller, G. W., Stirling, D. I., & Chopra, R. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.05.014 · Cited by 310
Metadata
- Authors
- Schett, G., Wollenhaupt, J., Papp, K., Joos, R., Rodrigues, J. F., Vessey, A. R., Hu, C., Stevens, R., & de Vlam, K. L.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2012-09-28
- Volume
- 64
- Issue
- 10
- Pages
- 3156-3167
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W1981700374
- Cited by
- 205
- References
- 0
- FWCI
- 21.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double‐blind, placebo‐controlled study. https://app.cochat.ai/papers/10.1002/art.34627
- The paper
- Schett, G., Wollenhaupt, J., Papp, K., Joos, R., Rodrigues, J. F., Vessey, A. R., Hu, C., Stevens, R., & de Vlam, K. L. (2012). Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double‐blind, placebo‐controlled study. Arthritis & Rheumatism. https://doi.org/10.1002/art.34627
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.